{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:27:46Z","timestamp":1787502466021,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2018-1-2151"],"award-info":[{"award-number":["2018-1-2151"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The accurate information about lymphoma burden at national and provincial levels remains unknown in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following the general analytical strategy used in GBD 2016, the age-, sex-, and province-specific incidence, mortality, and prevalence of lymphoma in China were analyzed. Trends in the incidence, mortality, prevalence, and disability-adjusted life years (DALYs) due to Hodgkin\u2019s lymphoma (HL) and non-Hodgkin\u2019s lymphoma (NHL) were assessed from 2006 to 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      It was estimated that there were 75,400 new cases and 40,500 deaths of lymphoma in 2016 in China, of which 6900 new cases and 2900 deaths were due to HL, while 68,500 new cases and 37,600 deaths were due to NHL. The age-standardized incidence rate (ASIR), mortality rate (ASMR), and prevalence rate (ASPR) per 100,000 were 0.46, 0.19, and 1.75 for HL, and 4.29, 2.45, and 14.9 for NHL, respectively. An upward trend with age in incidence and mortality was observed. Males had higher incidence and mortality rates than females in all age groups. Sociodemographic index had a correlation with the ASIR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.75), ASMR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.74), ASPR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.84), and age-standardized DALYs (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.75) of HL, as well as with the ASIR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.80), ASPR (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.83), and age-standardized DALYs (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.33) of NHL. From 2006 to 2016, the age-standardized DALYs of HL decreased significantly, while the age-standardized DALYs of NHL increased from 2006 to 2013 and remained stable from 2013 to 2016.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The burden of lymphoma in China showed unexpected patterns varied by sex, age, and provinces, with an increased trend of NHL and a decreased trend of HL from 2006 to 2016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-019-0785-7","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:01:33Z","timestamp":1574139693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Burden of lymphoma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016"],"prefix":"10.1186","volume":"12","author":[{"name":"Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"issue":"11","key":"785_CR1","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Fitzmaurice","year":"2018","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2018;4(11):1553\u201368.","journal-title":"JAMA Oncol."},{"issue":"10100","key":"785_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","unstructured":"GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151\u2013210.","journal-title":"Lancet"},{"issue":"6","key":"785_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"785_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108.","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"785_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"785_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-019-0706-9","volume":"12","author":"W Liu","year":"2019","unstructured":"Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12(1):22.","journal-title":"J Hematol Oncol."},{"issue":"10100","key":"785_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","volume":"390","author":"GBD 2016 DALYs and HALE Collaborators","year":"2017","unstructured":"GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260\u2013344.","journal-title":"Lancet"},{"issue":"10100","key":"785_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359.","journal-title":"Lancet"},{"issue":"10100","key":"785_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","volume":"390","author":"GBD 2016 Risk Factors Collaborators","year":"2017","unstructured":"GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345\u2013422.","journal-title":"Lancet"},{"key":"785_CR10","first-page":"1):1","volume":"30","author":"W Chen","year":"2018","unstructured":"Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30:1):1\u201312.","journal-title":"Chin J Cancer Res."},{"issue":"10","key":"785_CR11","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/annonc\/mdx342","volume":"28","author":"F Islami","year":"2017","unstructured":"Islami F, Chen W, Yu XQ, Lortet-Tieulent J, Zheng R, Flanders WD, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol. 2017;28(10):2567\u201374.","journal-title":"Ann Oncol."},{"issue":"19","key":"785_CR12","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med."},{"issue":"4","key":"785_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med."},{"issue":"17","key":"785_CR14","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1002\/cncr.30739","volume":"123","author":"N Howlader","year":"2017","unstructured":"Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123(17):3326\u201334.","journal-title":"Cancer."},{"issue":"4","key":"785_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/MLR.0000000000000486","volume":"54","author":"MD Danese","year":"2016","unstructured":"Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54(4):343\u20139.","journal-title":"Med Care."},{"issue":"10134","key":"785_CR16","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(18)30323-4","volume":"391","author":"S Jan","year":"2018","unstructured":"Jan S, Laba TL, Essue BM, Gheorghe A, Muhunthan J, Engelgau M, et al. Action to address the household economic burden of non-communicable diseases. Lancet. 2018;391(10134):2047\u201358.","journal-title":"Lancet."},{"issue":"9818","key":"785_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)60278-5","volume":"379","author":"Q Meng","year":"2012","unstructured":"Meng Q, Xu L, Zhang Y, Qian J, Cai M, Xin Y, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805\u201314.","journal-title":"Lancet."},{"issue":"10002","key":"785_CR18","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/S0140-6736(15)00342-6","volume":"386","author":"Q Meng","year":"2015","unstructured":"Meng Q, Fang H, Liu X, Yuan B, Xu J. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015;386(10002):1484\u201392.","journal-title":"Lancet."},{"issue":"10091","key":"785_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298\u2013310.","journal-title":"Lancet."},{"key":"785_CR20","doi-asserted-by":"crossref","first-page":"725219","DOI":"10.1155\/2011\/725219","volume":"2011","author":"P Shenoy","year":"2011","unstructured":"Shenoy P, Maggioncalda A, Malik N, Flowers CR. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol. 2011;2011:725219.","journal-title":"Adv Hematol."},{"issue":"6","key":"785_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/1055-9965.EPI-13-0040","volume":"22","author":"MS Shiels","year":"2013","unstructured":"Shiels MS, Engels EA, Linet MS, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1069\u201378.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"4","key":"785_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T, Clarke CA, Li J, Hall HI, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536\u201345.","journal-title":"Br J Haematol."},{"issue":"1","key":"785_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4143\/crt.2017.093","volume":"50","author":"H Lee","year":"2018","unstructured":"Lee H, Park HJ, Park EH, Ju HY, Oh CM, Kong HJ, et al. Nationwide statistical analysis of lymphoid malignancies in Korea. Cancer Res Treat. 2018;50(1):222\u201338.","journal-title":"Cancer Res Treat."},{"issue":"20","key":"785_CR24","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood."},{"issue":"6","key":"785_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1182\/blood-2011-02-336065","volume":"118","author":"ET Chang","year":"2011","unstructured":"Chang ET, Canchola AJ, Cockburn M, Lu Y, Wang SS, Bernstein L, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study. Blood. 2011;118(6):1591\u20139.","journal-title":"Blood."},{"issue":"48","key":"785_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jncimonographs\/lgu012","volume":"2014","author":"SS Wang","year":"2014","unstructured":"Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):66\u201375.","journal-title":"J Natl Cancer Inst Monogr."},{"issue":"6","key":"785_CR27","doi-asserted-by":"publisher","first-page":"e99857","DOI":"10.1371\/journal.pone.0099857","volume":"9","author":"G Xiong","year":"2014","unstructured":"Xiong G, Zhang B, Huang MY, Zhou H, Chen LZ, Feng QS, et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014;9(6):e99857.","journal-title":"PLoS One."},{"issue":"47","key":"785_CR28","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550\u20137.","journal-title":"Vaccine."},{"issue":"3","key":"785_CR29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ijc.31385","volume":"143","author":"BA Bassig","year":"2018","unstructured":"Bassig BA, Willhauck-Fleckenstein M, Shu XO, Koh WP, Gao YT, Purdue MP, et al. Serologic markers of viral infection and risk of non-Hodgkin lymphoma: a pooled study of three prospective cohorts in China and Singapore. Int J Cancer. 2018;143(3):570\u20139.","journal-title":"Int J Cancer."},{"issue":"2","key":"785_CR30","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(18)30488-1","volume":"7","author":"W Chen","year":"2019","unstructured":"Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019;7(2):e257\u201369.","journal-title":"Lancet Glob Health."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0785-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T23:03:03Z","timestamp":1605654183000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0785-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0785-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}